99-12793. Blood Products Advisory Committee; Notice of Meeting  

  • [Federal Register Volume 64, Number 97 (Thursday, May 20, 1999)]
    [Notices]
    [Pages 27580-27581]
    From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
    [FR Doc No: 99-12793]
    
    
    -----------------------------------------------------------------------
    
    DEPARTMENT OF HEALTH AND HUMAN SERVICES
    
    Food and Drug Administration
    
    
    Blood Products Advisory Committee; Notice of Meeting
    
    AGENCY: Food and Drug Administration, HHS.
    
    ACTION: Notice.
    
    -----------------------------------------------------------------------
    
        This notice announces a forthcoming meeting of a public advisory 
    committee of the Food and Drug Administration (FDA). The meeting will 
    be open to the public.
        Name of Committee: Blood Products Advisory Committee.
        General Function of the Committee: To provide advice and 
    recommendations to the agency on FDA's regulatory issues.
        Date and Time: The meeting will be held on June 17, 1999, 8 a.m. to 
    5 p.m. and June 18, 1999, 8 a.m. to 3 p.m.
        Location: DoubleTree Hotel, 1750 Rockville Pike, Rockville, MD.
        Contact Person: Linda A. Smallwood, Center for Biologics Evaluation 
    and Research (HFM-350), Food and Drug Administration, 1401 Rockville 
    Pike, Rockville, MD 20852-1448, 301-827-3514, or FDA Advisory Committee 
    Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC 
    area), code 19516. Please call the Information Line for up-to-date 
    information on this meeting.
        Agenda: On June 17, 1999, in the morning, the committee will 
    discuss and provide recommendations on inadvertent contamination of 
    plasma pools for fractionation: Risk issues. In the afternoon, the 
    committee will discuss strategies for insuring compliance in the plasma 
    fractionation industry, and the supply and demand of plasma 
    derivatives. On June 18, 1999, the committee will hear informational 
    presentations on the blood action plan and the device action plan, 
    discuss and provide recommendations on the topic of deferral of blood 
    donors at risk of malaria, and discuss and provide comments on the 
    topic of HTLV supplemental tests.
        Procedure: Interested persons may present data, information, or 
    views, orally or in writing, on issues pending before the committee. 
    Written submissions may be made to the contact
    
    [[Page 27581]]
    
    person by June 7, 1999. Oral presentations from the public will be 
    scheduled between approximately 10 a.m. and 10:30 a.m.; 1:30 p.m. and 2 
    p.m.; and 4 p.m. and 4:30 p.m. on June 17, 1999, and between 10:30 a.m. 
    and 11 a.m. and 2 p.m. and 2:30 p.m. on June 18, 1999. Time allotted 
    for each presentation may be limited. Those desiring to make formal 
    oral presentations should notify the contact person before June 7, 
    1999, and submit a brief statement of the general nature of the 
    evidence or arguments they wish to present, the names and addresses of 
    proposed participants, and an indication of the approximate time 
    requested to make their presentation.
        Notice of this meeting is given under the Federal Advisory 
    Committee Act (5 U.S.C. app. 2).
    
        Dated: May 14, 1999.
    Michael A. Friedman,
    Deputy Commissioner for Operations.
    [FR Doc. 99-12793 Filed 5-19-99; 8:45 am]
    BILLING CODE 4160-01-F
    
    
    

Document Information

Published:
05/20/1999
Department:
Food and Drug Administration
Entry Type:
Notice
Action:
Notice.
Document Number:
99-12793
Pages:
27580-27581 (2 pages)
PDF File:
99-12793.pdf